Admetsys, a startup developing artificial pancreas tech for hospitals and surgical care, won an investment from T1D Exchange. The terms of the financing were not disclosed.
A collaboration between the 2 groups is part of T1D Exchange’s initiative to support the development of automated insulin delivery technology, according to the organization.
Get the full story at our sister site, Drug Delivery Business News.
The post Artificial pancreas startup lands funding support from T1D Exchange appeared first on MassDevice.